Exploratory analysis of the economically justifiable price of reslizumab for asthma severe in Colombia
The economically justifiable cost for reslizumab in Colombia is between U106 to U$349per dose, depending on the WTP used to decide its implementation. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country.
Authors
- Jefferson Antonio Buendía (ORCID: https://orcid.org/0000-0003-2404-6612)
- Andrés F. Zuluaga (ORCID: https://orcid.org/0000-0001-5656-4153)
Institutions
- Universidad de Antioquia (CO)
Publication Details
- Journal
- BMC Public Health
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1186/s12889-025-23205-1
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16